Company Overview of Gan & Lee Pharmaceutical, Ltd.
Gan & Lee Pharmaceutical, Ltd., a pharmacological company, engages in the research and development, manufacture, and distribution of biosynthetic human insulin and analogs primarily in China, Europe, South America, and North Africa. Its products include Basalin, an insulin glargine injection; GanLee pen, a pen-style insulin injector; and Prandilin, an insulin lispro. The company was founded in 1998 and is based in Beijing, China.
Room 1805 Floor 18
Building C, Oriental Media Center
No. 4 Guanghua Road
Founded in 1998
86 10 8559 7868
86 10 8559 7851
Key Executives for Gan & Lee Pharmaceutical, Ltd.
Gan & Lee Pharmaceutical, Ltd. Key Developments
Similar Private Companies By Industry
|3D BioOptima Co. Ltd.||Asia|
|Adagene (Suzhou) Limited||Asia|
|AGCU ScienTech Incorporation||Asia|
|Anhui Life Co.,Ltd.||Asia|
|Anhui Puyuan Biotechnology Co., Ltd.||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Gan & Lee Pharmaceutical, Ltd., please visit www.ganlee.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.